Roth Capital Maintains Buy on FitLife Brands, Raises Price Target to $25
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
Get Free Real-Time Notifications for Any Stock
Analyst Views on FTLF
About FTLF
About the author
FitLife Brands Indicates Continued Margin Strain and Weak Consumer Demand After Acquiring Irwin Naturals
Management Overview: FitLife Brands reported a 47% year-over-year revenue increase to $23.5 million in Q3 2025, largely driven by the acquisition of Irwin Naturals, which contributed $6.8 million in revenue during the quarter. However, gross margin declined to 37.2% from 43.8% due to increased costs and integration challenges.
Financial Performance: The company experienced a drop in net income to $0.9 million from $2.1 million in the previous year, attributed to merger-related expenses and lower gross margins. MusclePharm showed strong organic growth of 55%, while MRC faced ongoing headwinds.
Consumer Trends and Challenges: Management noted signs of consumer weakness, including declining Amazon subscriber counts and reduced wholesale orders. They anticipate continued cost pressures, particularly from rising whey protein prices, and plan to implement price increases for MusclePharm products.
Outlook and Strategic Focus: FitLife Brands aims to optimize margins and manage operational complexities while navigating a challenging macro environment. The company is shifting Irwin's sales strategy towards online channels, which may introduce execution risks but is expected to enhance revenue over time.
Cresco Labs Inc. (CRLBF) Posts Q3 Loss but Exceeds Revenue Projections
Cresco Labs Quarterly Performance: Cresco Labs Inc. reported a quarterly loss of $0.05 per share, missing the Zacks Consensus Estimate of a loss of $0.03, and showing a decline in revenue to $164.91 million compared to $179.78 million a year ago.
Earnings Outlook and Stock Rating: The company's earnings outlook is currently unfavorable, resulting in a Zacks Rank #4 (Sell), indicating expected underperformance in the near future, with consensus estimates for the upcoming quarter at -$0.03 EPS on $163.65 million in revenues.
Market Comparison: Cresco Labs shares have increased by about 9.5% since the beginning of the year, underperforming compared to the S&P 500's gain of 14.3%, raising concerns about future stock performance.
Industry Context: The Medical - Products industry, to which Cresco Labs belongs, is currently ranked in the bottom 35% of Zacks industries, suggesting that the overall industry outlook could significantly impact the stock's performance.
